Publikationen in Zusammenarbeit mit Forschern von Instituto de Investigación Sanitaria Biodonostia (19)

2021

  1. Amyotrophic lateral sclerosis (ALS), cancer, autoimmunity and metabolic disorders: An unsolved tantalizing challenge

    British Journal of Pharmacology, Vol. 178, Núm. 6, pp. 1269-1278

  2. Does Extended Interval Dosing Natalizumab Preserve Effectiveness in Multiple Sclerosis? A 7 Year-Retrospective Observational Study

    Frontiers in Immunology, Vol. 12

2020

  1. Correction to: Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats (Psychopharmacology, (2020), 237, 8, (2419-2431), 10.1007/s00213-020-05544-6)

    Psychopharmacology

  2. Disrupted salience network dynamics in Parkinson's disease patients with impulse control disorders

    Parkinsonism and Related Disorders, Vol. 70, pp. 74-81

  3. Functional inhibitory control dynamics in impulse control disorders in Parkinson's disease

    Movement Disorders, Vol. 35, Núm. 2, pp. 316-325

  4. Motor impulsivity and delay intolerance are elicited in a dose-dependent manner with a dopaminergic agonist in parkinsonian rats

    Psychopharmacology, Vol. 237, Núm. 8, pp. 2419-2431

2019

  1. Nigrostriatal dopamine transporter availability, and its metabolic and clinical correlates in Parkinson’s disease patients with impulse control disorders

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 46, Núm. 10, pp. 2065-2076

  2. Pramipexole-induced impulsivity in mildparkinsonian rats: a model of impulse control disorders in Parkinson's disease

    Neurobiology of Aging, Vol. 75, pp. 126-135

2018

  1. Ratios of proteins in cerebrospinal fluid in Parkinson's disease cognitive decline: prospective study

    Movement Disorders, Vol. 33, Núm. 11, pp. 1809-1813

  2. Using Kinect to classify Parkinson's disease stages related to severity of gait impairment

    BMC Bioinformatics, Vol. 19, Núm. 1

2017

  1. Tau/α-synuclein ratio and inflammatory proteins in Parkinson's disease: An exploratory study

    Movement Disorders, Vol. 32, Núm. 7, pp. 1066-1073

2016

  1. Biomarkers for dementia and mild cognitive impairment in Parkinson's disease

    Movement Disorders, Vol. 31, Núm. 6, pp. 861-881

  2. Patrón geográfico de la mortalidad por enfermedad de Parkinson en España y su asociación con los niveles de plomo en el aire

    Medicina Clinica, Vol. 147, Núm. 11, pp. 481-487

  3. Trends in motor neuron disease: association with latitude and air lead levels in Spain

    Neurological Sciences, Vol. 37, Núm. 8, pp. 1271-1275

2015

  1. Cambios en la sustancia gris en pacientes con enfermedad de parkinson y bloqueos de la marcha

    Revista de Neurologia

  2. Dyskinesias and impulse control disorders in Parkinson's disease: From pathogenesis to potential therapeutic approaches

    Neuroscience and Biobehavioral Reviews, Vol. 56, pp. 294-314

  3. Parkinsonism, cognitive deficit and behavioural disturbance caused by a novel mutation in the polymerase gamma gene

    Journal of the Neurological Sciences, Vol. 350, Núm. 1-2, pp. 93-97

  4. The Relationship Between Atrophy and Hypometabolism: Is It Regionally Dependent in Dementias?

    Current Neurology and Neuroscience Reports, Vol. 15, Núm. 7

2014

  1. Anti-TNF-α therapy in the management of severe neurosarcoidosis: A report of five cases from a single centre and literature review

    Clinical and Experimental Rheumatology, Vol. 32, Núm. 2, pp. 275-284